Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® [Bictegravir/Emtricitabine/Tenofovir Alafenamide] in Virologically Suppressed People With HIV-1 [ARTISTRY 2] (NCT06333808)
ARTISTRY-2
This trial is Currently recruiting
Registration number NCT06333808
Program & service
This trial is being run with the Infectious Diseases service, and as part of the Infectious Diseases program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor James McMahon
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.